Skip Navigation

Cardiovascular Research 2003 60(3):465-467; doi:10.1016/j.cardiores.2003.10.017
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eickelberg, O.
Right arrow Articles by Grimminger, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eickelberg, O.
Right arrow Articles by Grimminger, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

The tantalizing triplet of pulmonary hypertension—BMP receptors, serotonin receptors, and angiopoietins

Oliver Eickelberg*, Michael E Yeager and Friedrich Grimminger

Department of Medicine, University of Giessen School of Medicine, Aulweg 123, 35392 Giessen, Germany

*Corresponding author. Tel.: +49-641-9942300; fax: +49-641-9942309. Email address: oliver.eickelberg@innere.med.uni-giessen.de

The first 10% of the full text of this article appears below.

See article by Blanpain et al. (pages 518–528) in this issue.

Not many diseases have attracted as much attention by the basic and clinical research community during the last several years as has idiopathic pulmonary arterial hypertension (IPAH, formerly primary pulmonary hypertension). IPAH is a severe and progressive disease localized exclusively to the lung, which exhibits an abnormally elevated precapillary pulmonary vascular resistance due to vasoconstriction and remodelling of the pulmonary vascular system. The underlying histological abnormalities consistently found in severe disease are obstructive and concentric lesions of small pulmonary resistance arterioles, which lead to an elevated pulmonary arterial pressure of >25 mm Hg at rest or >30 mm Hg during exercise. These lesions are thought to be due to enhanced proliferation of endothelial and/or smooth muscle cells or to the local transformation of quiescent fibroblasts into smooth muscle cells. The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
J. Sevilla-Perez, M. Konigshoff, G. Kwapiszewska, O. V. Amarie, W. Seeger, N. Weissmann, R. T. Schermuly, R. E. Morty, and O. Eickelberg
Shroom expression is attenuated in pulmonary arterial hypertension
Eur. Respir. J., October 1, 2008; 32(4): 871 - 880.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. E. Morty, B. Nejman, G. Kwapiszewska, M. Hecker, A. Zakrzewicz, F. M. Kouri, D. M. Peters, R. Dumitrascu, W. Seeger, P. Knaus, et al.
Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension
Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1072 - 1078.
[Abstract] [Full Text] [PDF]